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Hepatocellular carcinoma �HCC�� is t�e most frequent 
primary malignancy of t�e liver and accounts for as 
many as one million deat�s worldwide in a year. In some 
parts of t�e world it is t�e most common form of internal 
malignancy and t�e most common cause of deat� from 
cancer [1]. Well-known risk factors of �epatocellular 
carcinoma includes �epatitis B virus �HBV���� �epatitis C 
virus �HCV���� aflatoxins�� alco�ol and oral contraceptives. 
Smoking�� androgenic steroids and diabetes mellitus 
are also suspected risk factors [�]. One approac� to 
control liver cancer is c�emoprevention — w�en disease 
is prevented�� slowed or reversed substantially by t�e 
administration of one or more non-toxic naturally occur-
ring or synt�etic agents. In t�is regard�� recently naturally 
occurring polyp�enols are receiving increased attention 
because of t�eir promising efficacy in several cancer 
models [�]. Silymarin is one of suc� naturally occurring 
compounds isolated from Silybum marianum�� w�ic� �as 
s�own to �ave significant anticancer effect on several 
cancers bot� in vitro and in vivo [���].
Classically�� a marker is synt�esized by t�e tumor and 
released into t�e circulation�� but it may be produced by 
normal tissues in response to invasion by cancer cells 
[1�]. A variety of substances�� including enzymes�� �or-
mones�� antigens�� and proteins may be considered as 
tumor markers. Analysis of tumor markers can be used 
as an indicator of tumor response to t�erapy. Sensitive 
and specific liver cancer marker enzymes are used 
as indicators of liver injury. Analysis of t�ese marker 
enzymes reflects mec�anisms of cellular damage 
and subsequent release of proteins and extracellular 
turnover [11]. Lipid peroxidation generates a complex 
variety of products�� many of w�ic� are reactive electro-
p�iles some of t�ese react wit� protein and DNA and as 
a result are toxic and mutagenic [1�]. �alondialde�yde 
��DA�� is one of products of lipid peroxidation t�at reacts 
wit� DNA to produce �DA-DNA adducts�� w�ic� �ave 
been implicated in t�e induction of G→T transversions 
and A→G transitions [1�]. T�e ability of �DA-DNA ad-
ducts to induce frame s�ift mutations in sequences for 
genetic instability is emerging as a possible direct link 
between oxidative stress and �uman cancers [1��� 15]. 
T�us�� t�e purpose of present study is to evaluate t�e 
effect of silymarin on t�e level of tumor markers�� and 
�DA-DNA adducts formation during N-nitrosodiet�yl-
amine induced �epatocellular carcinoma in rats. 
MATERIALS AND METHODS
Animals. Wistar male rats weig�ing about 15��18� g 
were obtained from Tamilnadu Veterinary & Animal Sci-
ence University �TANUVAS���� �ad�avaram�� C�ennai�� 
India. T�e animals were �oused in cages under proper 
environmental conditions and were fed wit� a commer-
cial pelletted diet ��/s Hindustan foods Ltd.�� Bangalore�� 
India��. T�e animals �ad free access to water. 
Chemicals. N-nitrosodiet�ylamine �NDEA�� and 
silymarin were manufactured by Sigma c�emical Co.�� 
�St. Louis�� �O�� USA��. All ot�er c�emicals used were 
from SRL ��umbai�� India��.
Experimental design. T�e experimental animals 
were divided into five groups �as s�own in Fig. 1���� 6 ani-
mals per group. Rats from group 1 �normal control�� 
were fed wit� standard diet and pure drinking water; 
in group � �epatocellular carcinoma was induced 
by providing �.�1% NDEA t�roug� drinking water 
for 15 weeks as described in [16]; rats from group 
� were treated wit� 1��� ppm silymarin alone in diet 
for 16 weeks; rats from group � were pretreated wit� 
1��� ppm silymarin one week before t�e administra-
tion of �.�1% NDEA and received it till t�e end of t�e 
experiment �i.e. 16 weeks��; rats from group 5 were post 
treated wit� 1��� ppm silymarin for 5 weeks after t�e 
administration of NDEA for 1� weeks and received it till 
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t�e end of experiment. After t�e stipulated experimen-
tal period t�e rats were anaest�etized wit� diet�yl et�er 
followed by cervical decapitation. T�e experiments are 
performed after t�e approval of t�e Institutional Animal 
Et�ics Committee IAEC No. �1/���/�6.
Fig. 1. Experimental protocol
Analysis of alpha-fetoprotein (AFP) & car-
cinoembryonic antigen (CEA). AFP and CEA were 
measured in blood serum by c�emiluminescent im-
munoassay �Fully Automated ADVIA Centaur�� Bayer 
U.S.A. c�emiluminescence system��.
Biochemical studies. T�e blood samples were 
collected from t�e experimental animals�� liver tissue 
was removed and was�ed in ice-cooled saline�� and tis-
sues were c�illed in a beaker on cracked ice for 5 min�� 
and t�en minced wit� s�arp scissors. 1�% �omog-
enate was prepared in ice-cooled �.1 � Tris-HCl buffer 
�pH ��.���. Standard procedures were used to assay t�e 
various bioc�emical parameters. Protein content was 
estimated by Lowry et al. [1��]; activity of enzymes was 
valued as described elsew�ere �aminotransferases 
�AST�� ALT�� — [18]�� p�osp�atases �ACP�� ALP�� — [1�]�� 
lactate de�ydrogenase — [��]�� gamma-glutamyltrans-
ferase — [�1]�� 5�-nucleotidase — [��]��.
Immunohistochemical staining of MDA-DNA ad-
ducts. Immuno�istoc�emistry for �DA-DNA adducts 
was carried out according to Z�ang et al. [��]. Briefly�� 
tissue sections were deparraffinized in two c�anges of 
xylene at 6� ˚ C and re�ydrated t�roug� a graded series 
of alco�ols. T�en t�e slides were was�ed in 1 x PBS�� 
treated wit� RNase �1�� µl/ml�� at ��� ˚C for 1 ��� was�ed 
wit� 1 x PBS�� treated wit� proteinase K �1� µg/ml�� at 
room temperature for 1� min and was�ed. To dena-
ture t�e DNA�� t�e slides were incubated wit� � N HCl 
for 1� min and t�en was�ed wit� 5� m� Tris base for 
5 min�� bot� at room temperature. After was�ing wit� 1 x 
PBS�� slides were incubated wit� �.�% H�O� in met�anol 
at room temperature for �� min. Non-specific binding 
was blocked wit� �% BSA and t�e slides were incubated 
overnig�t at � ˚C wit� anti-�DA monoclonal antiserum 
number D1�A1 �Dr. P. Srinivasan�� Korea Atomic Energy 
Researc� Institute�� Korea��. T�e slides were was�ed in 
PBS and t�en incubated wit� anti-mouse HRP labelled 
secondary antibody �Genei�� Bangalore�� India�� for 1 � at 
room temperature. T�e peroxidase activity was visuali-
zed by treating slides wit� �����-diaminobenzidine tet-
ra�ydroc�loride �SRL�� �umbai�� India���� t�e slides were 
slig�tly counterstained wit� �eyer’s �ematoxylin. T�e 
labeling index was expressed as number of cells wit� 
positive staining per 1�� counted cells in five randomly 
selected fields at t�e magnification of objective �� x 
under lig�t microscope.
Statistical analysis. Data were evaluated wit� 
SPSS/1� software. Hypot�esis testing met�ods in-
cluded one way analysis of variance �ANOVA�� followed 
by least significant difference �LSD�� test. Statistical 
significance was defined as P values less t�an �.�5. All 
results were expressed as mean ± standard deviation.
RESULTS
T�e significant increase in t�e levels of AFP and 
CEA in t�e serum was observed in group � as com-
pared wit� group 1 �Fig. ���. Significant decrease of 
t�e level of t�ese tumor markers was demonstrated 
in t�e silymarin-treated animals from groups � and 5 
as compared wit� group �.
Fig. 2. Effect of silymarin on t�e levels of AFP and CEA in t�e serum 
of control and experimental groups of animals �n = 6 per group��. Re-
sults are expressed as mean ± SD. p < �.�5 compared wit� agroup1�� 
bgroup ��� cgroup ��� dgroup 5. Units: IU/mL for AFP�� ng/mL for CEA
Table. Effect of silymarin on the levels of AST, ALT, ACP, ALP, LDH, GGT and 5�NT in the serum of control and experimental group of animals
Groups AST ALT ACP ALP LDH GGT 5’NT
Group 1 3.90 ± 0.44 25.3 ± 2.85 27.23 ± 2.37 145.6 ± 16.6 1.42 ± 0.16 1.47 ± 0.17 3.09 ± 0.36
Group 2 7.58 ± 0.85acd 47.51 ± 4.99acd 48.8 ± 5.56acd 283.9 ±  32.37acd 2.48 ± 0.28acd 2.92 ±  0.29acd 6.19 ± 0.71acd
Group 3 3.82 ± 0.48 24.91 ± 2.83 26.24 ± 2.25 143 ± 16.3 1.4 ± 0.16 1.45 ± 0.16 3.08 ± 0.35
Group 4 5.3 ± 0.60abd 31.6 ± 3.60abd 33.42 ± 3.69abd 196 ± 22.30abd 1.71 ± 0.19abd 1.91 ± 0.21abd 4.31 ± 0.49abd
Group 5 6.42 ±  0.73abc 38.9 ± 4.43abc 40.7 ± 4.64abc 241 ± 28.4abc 2.09 ± 0.24abc 2.39 ± 0.27abc 5.15 ± 0.57abc
Note: Results are expressed as mean ± SD, (n = 6); p < 0.05 compared with  agroup 1, bgroup 2, cgroup 4, dgroup 5. Units: µmoles of pyruvate liberated 
mg protein per min for AST, ALT and LDH; µmoles of phenol liberated mg protein per min ACP and ALP; nmoles of p-nitroaniline formed mg protein per min 
for GGT; nmoles of Pi liberated mg protein per min for 5�NT.
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Animals from group � ex�ibited a significant in-
crease in t�e activity of AST�� ALT�� ACP�� ALP�� LDH�� GGT 
and 5�NT in blood serum as compared wit� group 1 
�Table��. Silymarin-treated animals from groups � and 
5 s�owed a significant decrease in t�e levels of t�ese 
enzymes w�en compared wit� group � �animals wit� 
NDEA-induced �epatocarcinoma��. T�e activity of AST 
and ALT was significantly decreased in t�e liver tissue 
of animals from group � as compared wit� group 1 
�Fig. ����� silymarin-treated animals �groups � and 5�� 
s�owed a significant increase in t�e level of transami-
nases as compared wit� group �. T�e activity of ACP�� 
ALP�� LDH�� GGT and 5�NT was significantly increased in 
t�e liver tissue of animals from group � as compared 
wit� group 1. T�ere was a significant decrease in t�e 
activity of t�ese enzymes in silymarin-treated groups 
as compared wit� group �.
Fig. 3. Effect of silymarin on t�e activity of AST�� ALT�� ACP�� ALP�� LDH�� 
GGT and 5’NT in t�e liver of control and experimental groups of 
animals �n = 6 per group��. Results are expressed as mean ± SD. p 
< �.�5 compared wit� agroup 1�� bgroup ��� cgroup ��� dgroup 5. Units: 
µmoles of pyruvate liberated mg protein per min for AST�� ALT and 
LDH; µmoles of p�enol liberated mg protein per min for ACP and 
ALP; nmoles of p-nitroaniline formed mg protein per min for GGT; 
nmoles of Pi liberated mg protein per min for 5�NT
As it was s�own by immuno�istoc�emical analysis 
of liver sections�� t�e �DA-DNA adducts were ob-
served in �% of �epatocytes in normal control animals 
�Fig. ��� a��. T�e rate of �epatocytes w�ic� were positive 
to �DA-DNA adducts was ��%�� �.�6%�� 18% & ��% in 
t�e liver sections from NDEA-induced �epatocarcinoma 
�Fig. ��� b���� silymarin alone �Fig. ��� c���� silymarin pretreat-
ed group �Fig. ��� d���� and silymarin post-treated animals 
�Fig. ��� e�� respectively. T�e grap�ical representation of 
% positive cells for �DA-DNA is s�own in Fig. ��� f.
DISCUSSION 
During carcinogenesis�� some enzymes can be used 
as an bioc�emical indicators of tumor response to 
t�erapy [11]. Hepatospecific enzymes were activated 
w�en �epatocellular damage gave rise to abnormali-
ties of liver function and t�ese enzymes are remarkably 
increased in HCC. AST and ALT activities in blood serum 
are generally accepted as an index of liver damage and 
t�is tendency is also known to be distinct in rodents [16]. 
T�ere was a good correlation between t�e activities of 
ALT and AST wit� tumor volume during t�erapy. Rocc�i 
et al. [��] reported t�at t�ere was an increase in t�e levels 
of t�ese transaminases activity in serum of HCC patients. 
In concurrent wit� t�e above findings an elevated serum 
aminotransferase activities were observed in animals 
bearing HCC wit� simultaneous decrease in t�e liver 
tissue; silymarin treatment significantly attenuated t�is 
alteration t�ereby s�owing its anticarcinogenic activity.
Elevation of alkaline p�osp�atase is one of t�e signs�� 
suggesting space-occupying lesions in t�e liver. An in-
creased activity of ACP and ALP was seen in blood serum 
and liver of animals wit� HCC�� t�is may be due to t�e 
disturbance in secretory activity or due to altered gene 
expression in t�ese conditions. Development of tumor 
results in tissue damage t�at lead to t�e release of ALP 
into circulation [�5] and t�is enzyme level �ave been el-
evated in blood serum and liver tissue of t�e tumor-bear-
ing animals and t�is elevation is significantly suppressed 
by t�e supplementation of silymarin in diet. GGT �as 
been s�own to play an important role in t�e metabolism 
of foreign substances and also during cell growt� and 
differentiation [�6] and is overexpressed in tumor cells 
resistant to t�erapeutic drugs [���]. Experimental stud-
ies �ave s�own t�at GGT was strikingly activated during 
t�e course of �epatocarcinogenesis induced by several 
�epatocarcinogens in animals [�8]; c�emical carcino-
gens may initiate some systematic effects t�at induce 
GGT synt�esis [��]. T�is elevation reflects t�e progress 
of carcinogenesis�� since its activity correlates wit� tumor 
growt� rate�� differentiation and survival of t�e �ost [��]; 
in concurrent wit� above findings t�ere was an increase 
in t�e levels of GGT in t�e serum and liver of animals 
bearing HCC. T�is elevation indicates t�e basic tumor 
burden�� and silymarin treatment significantly decreased 
t�e elevation of t�e level of t�is enzyme.
5�nucleotidase was found to be elevated in t�e 
animals wit� solid tumors [�1]. T�e increased activ-
ity of t�is enzyme seems to �ave originated from t�e 
proliferating tumor cells [��]. Elevated activities of 
5�nucleotidase in carcinoma of liver and leukemia were 
reported [11�� ��]. In our study correlatively increased 
activities of 5�nucleotidase were observed in blood 
serum and liver of t�e carcinogen administered ani-
mals�� and t�is elevation is significantly in�ibited in t�e 
animals treated wit� silymarin.
LDH is a fairly sensitive marker of solid neoplasm 
[��] and very �ig� LDH levels correlate wit� treatment 
failure [�5]; numerous reports revealed increased 
LDH activity in various types of tumors [1��� �6]. T�e 
elevated levels of LDH may be due to its overproduc-
tion by tumor cells. Proliferating malignant cells ex�ibit 
very �ig� rates of glycolysis�� w�ic� subsequently lead 
to elevated LDH activity [���]. T�e results of t�e pres-
ent study are in agreement wit� literature data and 
s�ow elevated levels of LDH in blood serum and liver 
of t�e NDEA administered rats�� and t�is elevation was 
attenuated in silymarin-treated rats.
Elevation of serum AFP levels �as been reported in 
several diseases including HCC [�8]. AFP along wit� CEA 
is most extensively used in t�e diagnosis of HCC [���� ��]. 
In our study also t�ere was an increased level of AFP and 
CEA in t�e carcinogen administered animals confirming 
t�e presence of HCC�� and silymarin treatment signifi-
cantly reduced t�e elevation of bot� AFP and CEA.
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�DA is a �ig�ly reactive electrop�ile�� capable of 
interacting wit� DNA to form �DA-DNA adducts [�1]�� 
t�at induce frame s�ift and base-pair substitution muta-
tions [1�]. T�e level of �DA-DNA adducts is found to be 
increased in several cancers [����5]. Recent evidence 
suggests t�at oxidative stress may contribute to genetic 
instability and promote tumor progression [1��� 15]. In 
t�e present study t�e levels of �DA-DNA adducts are 
increased in HCC-bearing animals�� and pre- and post-
silymarin treatment significantly reduced t�e formation 
of �DA-DNA adduct. So�� we can conclude t�at silymarin 
could be developed as a promising c�emot�erapeutic 
adjuvant for t�e treatment of liver cancer.
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ВЛИЯНИЕ СИЛИМАРИНА НА ГЕПАТОКАНЦЕРОГЕНЕЗ, 
ИНДУЦИРОВАННЫЙ У КРЫС N-НИТРОЗОДИЭТИЛАМИНОМ
Цель: изучить влияние силимарина на уровень экспрессии опухолевых и биохимических маркеров и формирование аддуктов 
малонового диальдегида с ДНК (MDA-DNA) при развитии гепатокар�иномы у крыс линии �истар.        Методы: стандартными 
биохимическими методами определяли активность ферментов в сыворотке крови и проводили иммуногистохимическое 
определение MDA-DNA в ткани печени крыс.     Результаты: показано, что при развитии злокачественной гепатокар�и-
номы в сыворотке крови животных значительно увеличивается количество альфа-фетопротеина, раковоэмбрионального 
антигена, активность аспартат- и аланинаминотрансферазы, щелочной и кислой фосфатазы, лактатдегидрогеназы, гамма-
глутамилтрансферазы и 5�-нуклеотидазы. При проведении иммуногистохимического исследования отмечали повышенное 
образование аддуктов MDA-DNA в ткани печени крыс со злокачественной гепатокар�иномой. При введении силимарина           
значительно снижался уровень указанных ферментов в сыворотке крови и формирование аддуктов MDA-DNA в ткани   
печени. Заключение: применение силимарина может быть эффективно для предупреждения развития злокачественной 
гепатокар�иномы, инду�ированной N-нитрозодиэтиламином у крыс, и этот препарат может быть многообещающим хи-
миотерапевтическим адъювантом для лечения рака печени.
Ключевые слова: MDA-DNA, альфафетопроеин, злокачественная гепатокар�инома,    N-нитрозодиэтиламин, силимарин, 
флавоноиды. 
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